Interferons Market Report 2026

The interferons market size has grown strongly in recent years. It will grow from $9.92 billion in 2025 to $10.54 billion in 2026 at a compound annual growth rate (CAGR) of 6.3%. The growth in the historic period can be attributed to limited availability of recombinant interferons, growing prevalence of hepatitis b and c, increasing incidence of melanoma and leukemia, reliance on conventional interferon therapies, expanding hospital pharmacy networks.

The interferons market size is expected to see strong growth in the next few years. It will grow to $13.7 billion in 2030 at a compound annual growth rate (CAGR) of 6.8%. The growth in the forecast period can be attributed to development of pegylated and long-acting interferons, increasing use in multiple sclerosis and renal cell carcinoma, expansion of online and retail pharmacy access, rising adoption of combination therapies, growing government support for immunotherapy programs. Major trends in the forecast period include rising adoption of interferon therapies for viral infections, increasing use of interferons in oncology treatments, expansion of multiple sclerosis treatment using interferon beta, growth in hospital and online pharmacy distribution channels, focus on development of long-acting and improved formulations.

The increasing incidence of cancer is expected to drive the growth of the interferon market in the coming years. Cancer is a group of diseases characterized by the uncontrolled growth of abnormal cells that can invade surrounding tissues and spread to other parts of the body. Interferons are used in the treatment of several types of cancer, including melanoma, Kaposi’s sarcoma, and certain leukemias. They are commonly administered as part of combination therapies, where they help enhance the body’s immune response against cancer cells. For example, in July 2024, according to the Australian Institute of Health and Welfare, an Australia-based government agency, an estimated 165,000 Australians were newly diagnosed with cancer in 2023, equivalent to more than 450 new cases each day, with males accounting for around 55% of diagnoses. Therefore, the rising burden of cancer is contributing to the growth of the interferon market.

Major companies operating in the interferon market are advancing innovative research programs, such as ADAR1 inhibitors and DHX9 inhibitors, to induce replication stress and cancer cell death in microsatellite-unstable tumors. ADAR1 inhibitors are designed to block ADAR1, a target associated with immune activation in cancer cells, where inhibition has been shown to trigger cell death in tumors with elevated type I interferon signaling. DHX9 inhibitors focus on small-molecule compounds that target DHX9, an RNA helicase involved in maintaining genomic stability in cancer cells, with inhibition leading to replication stress and cell death in certain tumor types. For instance, in October 2023, Accent Therapeutics, a US-based biopharmaceutical company, launched its XRN1 program, which aims to develop small-molecule inhibitors targeting the XRN1 enzyme, a key regulator of RNA degradation and innate immune signaling. This program is intended to treat tumors with heightened interferon signaling and enhance cancer cell death. As part of its precision oncology strategy, Accent Therapeutics presented preclinical validation data and progress updates on selective inhibitors for this target at the 35th AACR-NCI-EORTC Symposium.

In May 2024, CytomX Therapeutics Inc. partnered with Merck & Co., Inc. for an undisclosed amount. Through this collaboration, the companies aim to jointly develop innovative antibody-drug conjugates to improve both the efficacy and safety of cancer treatments. Merck & Co., Inc. is a US-based pharmaceutical company engaged in the research, development, manufacturing, and commercialization of a broad range of medicines and vaccines for multiple health conditions.

Major companies operating in the interferons market are Roche Holding AG, Merck & Co. Inc., Bristol-Myers Squibb Company, Biogen Inc., Bayer AG, Zydus Cadila Health Care Limited, Biosidus S.A., Nanogen Biopharmaceutical Co. Ltd., Amega Biotech Inc., Rhein Minapharm Biogenetics S.A.E., PROBIOMED S.A. de C.V., Schering-Plough Corporation, 3SBio Inc., Genentech Inc., Teva Pharmaceutical Industries Ltd., Biocad, Cipla Limited, Dr. Reddy's Laboratories Ltd., Hetero Drugs Limited.

North America was the largest region in the interferons market in 2025. Middle East is expected to be the fastest-growing region in the interferons market during the forecast period. The regions covered in the interferons market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the interferons market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the interferons market by increasing costs of imported biologics, recombinant proteins, and raw materials used in interferon production. Interferon alpha, beta, and gamma segments are particularly affected, with North America, Europe, and Asia-Pacific regions like China and India facing significant import duties. This has resulted in higher treatment costs and potential delays in availability. On the positive side, tariffs have encouraged domestic manufacturing, innovation in formulation technologies, and investment in local production capabilities.

The interferons market research report is one of a series of new reports that provides interferons market statistics, including interferons industry global market size, regional shares, competitors with a interferons market share, detailed interferons market segments, market trends and opportunities, and any further data you may need to thrive in the interferons industry. This interferons market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Interferons are naturally occurring substances that help support the body’s immune system in fighting diseases, including cancer. They are produced by white blood cells and other cells in the body, and they can also be manufactured in laboratories for therapeutic use in treating a range of medical conditions.

The primary types of interferons include interferon alpha, interferon beta, and interferon gamma. Interferon alpha is a cytokine produced by the innate immune system in response to environmental stimuli such as viral infections. These products are distributed through hospital pharmacies, online pharmacies, retail pharmacies, and other channels, and are used in the treatment of hepatitis B, hepatitis C, melanoma, leukemia, multiple sclerosis, and renal cell carcinoma.

The interferons market consists of sales of polypeptides, cytokine, and cell-surface receptors. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.